Clinical trials for a domestic
anti-cancer drug continue in Kazakhstan. In collaboration with the Kazakh
Research Institute of Oncology and Radiology, scientists are testing the
effectiveness and safety of the new medication. Its developer Dos Sarbassov shared the results of the tests. At the
first stage the drug was administered to 15 patients, initially in small doses
and then with their subsequent increase. During the study, scientists found a
significant slowdown in tumor growth, and in one case it was reduced by a third.
Additionally, the scientists confirmed that the drug showed no toxicity. In the
second phase of trials, scientists are working on determining the optimal
tolerable dose to enhance the drug’s effectiveness. The research will continue
for several more years before the unique medication is introduced to the
market.
«Once we obtain the results and
determine which type of oncology or cancer is most sensitive, we will move to
the third phase and then expand the trials to 1,000 people. Currently,
according to the rules of the first and second phases of clinical trials, we
are working with only one oncology center. As soon as we achieve results and
identify the type of cancer, we will conduct multicenter clinical trials in two
years,» Sarbassov said.
